$1.95—
NASDAQ
$1.95—
Imunon, Inc. is a biotechnology company focused on developing innovative therapies for cancer and infectious diseases. The company's lead product candidate, CLSN-001, is in clinical trials targeting solid tumors, which positions it uniquely within the oncology space, particularly in the U.S. and European markets.
Imunon primarily generates revenue through partnerships and collaborations with larger pharmaceutical companies for clinical trials. The company aims to monetize its proprietary drug candidates through licensing agreements and eventual product sales, leveraging its unique approach to immunotherapy.
Clinical trial results for CLSN-001 and other candidates
Partnership announcements or collaborations with larger pharma companies
Regulatory approvals from the FDA or EMA
Market sentiment towards biotech sector trends
Regulatory changes affecting drug approval processes
Technological disruptions in biotechnology and therapeutics
Emerging therapies from competitors in the oncology space
Potential for larger pharmaceutical companies to outpace smaller biotech firms
High debt levels relative to market cap and revenue
Liquidity risks due to negative cash flow
moderate - The biotechnology sector can be sensitive to economic cycles, as funding for R&D may fluctuate with economic conditions.
Higher interest rates can increase the cost of financing for biotech firms, impacting their ability to fund clinical trials and operations, potentially leading to lower valuations.
minimal - Imunon does not rely heavily on credit markets for its operations, but its high debt-to-equity ratio indicates some vulnerability.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has shown significant volatility, evidenced by a 1-year return of -66.7%.